- Brukinsa (Zanubrutinib)
- Imbruvica (Ibrutinib)
- Umbralisib (Ukoniq)
- Revlimid (Lenalidomide)
- Rituximab (Rituxan)
- Venetoclax
- Cladribine
- Carfilzomib
- Others
Marginal Zone Lymphoma Treatment Market was valued at USD 2.59 billion in 2022, and is poised to grow at a CAGR of 6.3% CAGR from 2023 to 2029. Marginal zone lymphoma is a slow-growing B-cell non-Hodgkin lymphoma that begins forming from certain areas of lymph tissue. There are three regions from where it begins such as the spleen, lymph nodes, and lymphoid tissue that contain a lot of B-cells. In some people, H. pylori infection can lead to the development of marginal zone lymphoma. The exact mechanism by which H. pylori infection causes marginal zone lymphoma is not fully understood, but it is thought to involve the production of inflammatory cytokines by the bacteria. The risk increases in a person of 65+ years of age with a weakened immune system. The prevalence of MZL is estimated to be about 2 cases per 100,000 people. The mortality rate for MZL is about 5%. All these numerical data indicated the prospect of the Marginal Zone Lymphoma (MZL) Treatment Market in the forecast period. There are several FDA-approved drugs available for the treatment of MZL. These drugs include Rituximab (Rituxan), Lenalidomide (Revlimid), Ibrutinib (Imbruvica), Zanubrutinib (Brukinsa). These drugs can be used to treat MZL in a variety of settings, including newly diagnosed MZL, relapsed or refractory MZL, and MZL that has spread to other parts of the body. The drug sales for MZL drugs are significant. In 2021, the global sales of MZL drugs were estimated to be over $1.5 billion. The United States and Europe are the two largest markets for MZL drugs. The FDA and the EU have approved a number of drugs for the treatment of MZL. These approvals are based on the results of clinical trials that have shown that these drugs can improve the survival and quality of life of patients with Marginal Zone Lymphoma (MZL).
Marginal Zone Lymphoma Treatment Market Key Developments:
- In February 2021, The U.S. Food and Drug Administration (FDA) announced the approval of UKONIQ™ (umbralisib), a once-daily, oral medication for the treatment of marginal zone lymphoma (MZL) that has returned or worsened following prior treatment with an anti-CD20 antibody.
Marginal Zone Lymphoma Treatment Market Summary
Study Period
2024-2030
Base Year
2023
CAGR
6.3%
Largest Market
Europe
Fastest Growing Market
North America
Marginal Zone Lymphoma Treatment Market Dynamics
The approved drugs market in MZL is expected to grow at a of 6.3% from 2023 to 2029. This growth in the Marginal Zone Lymphoma (MZL) Pharma Market is driven by the increasing prevalence of MZL, the availability of new and effective drugs, and the growing demand for personalized medicine. Several medications have received approval from the FDA and the EU for treating Marginal Zone Lymphoma (MZL) Disease. These approvals are based on clinical trial findings indicating these medications can increase patients with MZL's chances of survival and quality of life. These advancements in disease management and its prognosis through various research activities would ultimately drive the MZL treatment molecule sales as confirmatory results will bring more patients into the treatment option. Personalized treatment options for marginal zone lymphoma (MZL) are based on several factors, including the stage of the disease, the patient's age and overall health, and the specific genetic mutations present in the lymphoma cells. Personalized medicine can be used to identify the best treatment options for each patient. This is important because MZL is a heterogeneous disease, and different patients may respond differently to different treatments. Thus, increased preference for personalized medicine is expected to boost the Marginal Zone Lymphoma (MZL) Market Opportunity.
Europe Got Significant Share
Marginal Zone Lymphoma Treatment Market Regional Analysis
Based on regions, the market share is segmented into North America, Asia-pacific, Europe, the Middle East, and the African region. The two biggest markets for MZL medications are the United States and Europe. The prevalence of marginal zone lymphoma (MZL) in these regions has been increasing in recent years, and this increase is thought to be related to the aging of the population. MZL is a type of non-Hodgkin lymphoma that is most common in people over the age of 60. The risk of developing MZL increases with age, and the disease is rare in people under the age of 40. The overall scenario of MZL in the United States is that it is a relatively rare disease, but it is becoming more common. In 2022, an estimated 15,000 people in the United States will be diagnosed with MZL. The risk of developing MZL increases with age, and the disease is rare in people under the age of 40. MZL is slightly more common in men than in women. MZL is more common in Caucasians than in other racial groups. Thus, this increasing prevalence, along with advancements in R&D will propel the growth of Marginal Zone Lymphoma (MZL) Drug Sales in the forecast period.
Latin America
Europe
Asia Pacific
Middle East
North America
Key Features of the Reports
- The report provides granular level information about the market size, regional market share, historic market (2018 to 2022) and forecast (2023 to 2029)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments and startup’s details that are actively working in the market
- The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
- The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market
Marginal Zone Lymphoma Treatment Market Segmentation
By Drug Type
By Distribution Channel
- Retail Stores
- Hospital Pharmacy
By Geography
- North America
- Europe
- The Asia Pacific
- Latin America
- MEA
Frequently Asked Questions
The marginal zone lymphoma treatment market size is USD 526 million in 2022 and it is expected to reach USD 840 billion by 2028, growing at a 6.2% CAGR from 2023 to 2029.
The leading players in the Marginal Zone Lymphoma Treatment Market are Incyte Corporation, InnoCare Pharma, ENTEROME SA, Beijing Mabworks Biotech Co., Ltd., ADC Therapeutics, MEI Pharma, Inc., Genentech, Inc., Incyte Corporation, Novartis, AstraZeneca, Roche, Oncternal Therapeutics, Inc, Celgene, IGM Biosciences, Inc., Loxo Oncology, Genmab, ArQule, Sound Biologics, Adicet Bio, Inc, Celldex Therapeutics, TG Therapeutics, Velos Bio Inc., Newave Pharmaceutical Inc., among others
Historic years considered for the market study are 2018 through 2022, 2022 is considered as the base year for market estimation, and Seven years forecast is presented from 2023 – 2029.
| 1. Executive Summary |
| 2. Global Marginal Zone Lymphoma Treatment Market Introduction |
| 2.1.Global Marginal Zone Lymphoma Treatment Market - Taxonomy |
| 2.2.Global Marginal Zone Lymphoma Treatment Market - Definitions |
| 2.2.1.Drug Type |
| 2.2.2.Distribution Channel |
| 2.2.3.Region |
| 3. Global Marginal Zone Lymphoma Treatment Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4. Global Marginal Zone Lymphoma Treatment Market Analysis, 2018 - 2022 and Forecast 2023 - 2029 |
| 4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5. Global Marginal Zone Lymphoma Treatment Market By Drug Type, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 5.1. Brukinsa (Zanubrutinib) |
| 5.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Imbruvica (Ibrutinib) |
| 5.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Umbralisib (Ukoniq) |
| 5.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 5.4. Revlimid (Lenalidomide) |
| 5.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.4.3. Market Opportunity Analysis |
| 5.5. Rituximab (Rituxan) |
| 5.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.5.3. Market Opportunity Analysis |
| 5.6. Venetoclax |
| 5.6.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.6.3. Market Opportunity Analysis |
| 5.7. Cladribine |
| 5.7.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.7.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.7.3. Market Opportunity Analysis |
| 5.8. Carfilzomib |
| 5.8.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.8.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.8.3. Market Opportunity Analysis |
| 5.9. Others |
| 5.9.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.9.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.9.3. Market Opportunity Analysis |
| 6. Global Marginal Zone Lymphoma Treatment Market By Distribution Channel, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 6.1. Retail Stores |
| 6.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Hospital Pharmacy |
| 6.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 7. Global Marginal Zone Lymphoma Treatment Market By Region, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 7.1. North America |
| 7.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Europe |
| 7.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Asia Pacific (APAC) |
| 7.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 7.4. Middle East and Africa (MEA) |
| 7.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.4.3. Market Opportunity Analysis |
| 7.5. Latin America |
| 7.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 7.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.5.3. Market Opportunity Analysis |
| 8. North America Marginal Zone Lymphoma Treatment Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 8.1. Drug Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 8.1.1.Brukinsa (Zanubrutinib) |
| 8.1.2.Imbruvica (Ibrutinib) |
| 8.1.3.Umbralisib (Ukoniq) |
| 8.1.4.Revlimid (Lenalidomide) |
| 8.1.5.Rituximab (Rituxan) |
| 8.1.6.Venetoclax |
| 8.1.7.Cladribine |
| 8.1.8.Carfilzomib |
| 8.1.9.Others |
| 8.2. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 8.2.1.Retail Stores |
| 8.2.2.Hospital Pharmacy |
| 8.3. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 8.3.1.United States of America (USA) |
| 8.3.2.Canada |
| 9. Europe Marginal Zone Lymphoma Treatment Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 9.1. Drug Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1.Brukinsa (Zanubrutinib) |
| 9.1.2.Imbruvica (Ibrutinib) |
| 9.1.3.Umbralisib (Ukoniq) |
| 9.1.4.Revlimid (Lenalidomide) |
| 9.1.5.Rituximab (Rituxan) |
| 9.1.6.Venetoclax |
| 9.1.7.Cladribine |
| 9.1.8.Carfilzomib |
| 9.1.9.Others |
| 9.2. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.2.1.Retail Stores |
| 9.2.2.Hospital Pharmacy |
| 9.3. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.3.1.Germany |
| 9.3.2.France |
| 9.3.3.Italy |
| 9.3.4.United Kingdom (UK) |
| 9.3.5.Spain |
| 9.3.6.Rest of EU |
| 10. Asia Pacific (APAC) Marginal Zone Lymphoma Treatment Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 10.1. Drug Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1.Brukinsa (Zanubrutinib) |
| 10.1.2.Imbruvica (Ibrutinib) |
| 10.1.3.Umbralisib (Ukoniq) |
| 10.1.4.Revlimid (Lenalidomide) |
| 10.1.5.Rituximab (Rituxan) |
| 10.1.6.Venetoclax |
| 10.1.7.Cladribine |
| 10.1.8.Carfilzomib |
| 10.1.9.Others |
| 10.2. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1.Retail Stores |
| 10.2.2.Hospital Pharmacy |
| 10.3. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1.China |
| 10.3.2.India |
| 10.3.3.Australia and New Zealand (ANZ) |
| 10.3.4.Japan |
| 10.3.5.Rest of APAC |
| 11. Middle East and Africa (MEA) Marginal Zone Lymphoma Treatment Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 11.1. Drug Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1.Brukinsa (Zanubrutinib) |
| 11.1.2.Imbruvica (Ibrutinib) |
| 11.1.3.Umbralisib (Ukoniq) |
| 11.1.4.Revlimid (Lenalidomide) |
| 11.1.5.Rituximab (Rituxan) |
| 11.1.6.Venetoclax |
| 11.1.7.Cladribine |
| 11.1.8.Carfilzomib |
| 11.1.9.Others |
| 11.2. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1.Retail Stores |
| 11.2.2.Hospital Pharmacy |
| 11.3. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1.GCC Countries |
| 11.3.2.South Africa |
| 11.3.3.Rest of MEA |
| 12. Latin America Marginal Zone Lymphoma Treatment Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 12.1. Drug Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1.Brukinsa (Zanubrutinib) |
| 12.1.2.Imbruvica (Ibrutinib) |
| 12.1.3.Umbralisib (Ukoniq) |
| 12.1.4.Revlimid (Lenalidomide) |
| 12.1.5.Rituximab (Rituxan) |
| 12.1.6.Venetoclax |
| 12.1.7.Cladribine |
| 12.1.8.Carfilzomib |
| 12.1.9.Others |
| 12.2. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1.Retail Stores |
| 12.2.2.Hospital Pharmacy |
| 12.3. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1.Brazil |
| 12.3.2.Mexico |
| 12.3.3.Rest of LA |
| 13. Competition Landscape |
| 13.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 13.2.1.AbbVie |
| 13.2.2.Genentech |
| 13.2.3.Johnson & Johnson |
| 13.2.4.Novartis |
| 13.2.5.Pfizer |
| 13.2.6.Teva Pharmaceuticals |
| 14. Research Methodology |
| 15. Appendix and Abbreviations |
- Incyte Corporation
- InnoCare Pharma
- ENTEROME SA
- Beijing Mabworks Biotech Co. Ltd.
- ADC Therapeutics
- MEI Pharma Inc.
- Genentech Inc.
- Incyte Corporation
- Novartis
- AstraZeneca
- Kite Pharma
- Roche
- Oncternal Therapeutics Inc.
- Celgene
- IGM Biosciences
- Loxo Oncology
- Genmab
- Sound Biologics
- Adicet Bio
- Celldex Therapeutics
- Newave Pharmaceutical